# Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours

> **NCT00875433** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 60 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BIBW 2992

## Key facts

- **NCT ID:** NCT00875433
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2011-04
- **Final completion:** —
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2013-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00875433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00875433, "Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00875433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*